Compare HASI & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HASI | GRFS |
|---|---|---|
| Founded | 1981 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.2B |
| IPO Year | 2012 | N/A |
| Metric | HASI | GRFS |
|---|---|---|
| Price | $37.93 | $7.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $44.38 | $10.15 |
| AVG Volume (30 Days) | ★ 785.2K | 657.5K |
| Earning Date | 05-07-2026 | 07-28-2022 |
| Dividend Yield | ★ 4.20% | 1.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $400,502,000.00 | N/A |
| Revenue This Year | $79.17 | $4.49 |
| Revenue Next Year | $207.88 | $6.42 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $24.40 | $6.96 |
| 52 Week High | $44.13 | $11.14 |
| Indicator | HASI | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 60.27 |
| Support Level | $36.68 | $7.38 |
| Resistance Level | $39.75 | $8.24 |
| Average True Range (ATR) | 0.90 | 0.16 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 33.33 | 87.23 |
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition. The company's single reportable segment generates net investment and equity method investment income through investments in energy transition assets and infrastructure projects, as well as revenue through the gain on sale of assets and recurring asset management fees.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.